Loading clinical trials...

A Safety and Tolerability Study of ABT-126 in Elderly | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Safety and Tolerability Study of ABT-126 in Elderly

A Multiple Dose Study of Safety, Tolerability and Pharmacokinetics of ABT-126 in Elderly Subjects

NCT00867399•Abbott

Summary

The objectives of this study are to assess the safety, tolerability and pharmacokinetics of ABT-126 in elderly subjects.

Eligibility

Age

65 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy male or female subjects 65 years or greater.
•Has a MMSE score of 27 or higher.

Exclusion Criteria

•History of dementia including by not limited to Alzheimer's disease, Parkinson's disease and mult-infarct dementia.
•History of any significant neurological disease.
•Has an estimated creatinine clearance \< 30 mL/min

Locations (1)

Site Reference ID/Investigator# 17283

Orlando, Florida, United States

Key Dates

Start Date

March 1, 2009

Primary Completion Date

May 1, 2009

Last Updated

November 2, 2010

Enrollment

ACTUAL participants

Conditions

Alzheimer's Disease

Interventions

ABT-126

DRUG

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673

Alzheimer's Disease Psychosis

View study

RECRUITING

Lombard Cohort of Brain Health Services

NCT07457138

Subjective Cognitive Decline (SCD)Functional Cognitive Disorder+2 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 2, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Safety and Tolerability Study of ABT-126 in Elderly

Inclusion Criteria

Exclusion Criteria

ACP-204 in Adults With Alzheimer's Disease Psychosis

Lombard Cohort of Brain Health Services

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia